Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trichuris suis ova - Fortress Biotech

Next Previous
Drug Profile

Trichuris suis ova - Fortress Biotech

Alternative Names: CNDO-201; TSO; TSO 2500; TSO 7500

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Iowa Research Foundation
  • Developer Charite of Berlin; Dr Falk Pharma; Fortress Biotech; Hadassah Medical Organization; Icahn School of Medicine at Mount Sinai; National Institutes of Health (USA); University of Wisconsin-Madison
  • Class Eukaryota; Immunotherapies; Probiotics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Autistic disorder; Crohn's disease; Multiple sclerosis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Type 1 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 29 Jul 2016 Immanuel Krankenhaus Berlin terminates phase II TSORA trial in Rheumatoid arthritis (adjunctive therapy) in Germany (EudraCT2011-006344-71)
  • 05 May 2016 Charite University terminates phase II trial in Multiple sclerosis in Germany (EudraCT2009-015319-41)
  • 01 Feb 2016 Hadassah Medical Organization terminates a phase II trial in Autistic disorder in Israel due to lack of significant efficacy (NCT01734941)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top